<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05052125</url>
  </required_header>
  <id_info>
    <org_study_id>2019-002498-80 substudy</org_study_id>
    <nct_id>NCT05052125</nct_id>
  </id_info>
  <brief_title>Substudy of Protocol 2019-002498-80 - NCT04223050: Comparing Mortality for Low vs High Peripheral Oxygen Saturation in COPD-patients With Acute Exacerbation (O2flow-COPD)</brief_title>
  <official_title>Substudy: Oxygen Therapy in COPD Patients - Oxidative Stress and Mortality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mikkel Brabrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Region of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sydvestjysk Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      As protocol NCT04223050. This substudy furthermore investigates the role of oxidative stress&#xD;
      in the administration of oxygen in COPD patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies have shown that oxidative stress plays a critical role in the pathogenesis of COPD&#xD;
      and its comorbidities. Oxidative stress refers to a state in which the activity of oxidants&#xD;
      (e.g. reactive oxygen species (ROS)) outweighs that of antioxidants. ROS can be introduced&#xD;
      exogenously by for example cigarette smoke and atmospheric pollution, but is also produced&#xD;
      endogenously as a byproduct of ATP production in mitochondria or from immune cells during&#xD;
      oxidative burst. When high fractions of inspired oxygen are administered, excess O2 can lead&#xD;
      to formation of additional ROS, which depletes antioxidants and induces an inflammation with&#xD;
      leukocyte-derived inflammatory mediators migrating to the site of injury. In turn, this&#xD;
      causes cellular hypertrophy, increased surfactant secretion, and cellular influx of monocytes&#xD;
      and mast cells. During the final, fibrotic phase of oxygen toxicity, irreversible, persistent&#xD;
      destruction of the pulmonary lining have occurred with collagen disposition, thickening of&#xD;
      pulmonary interstitial space, and fibrosis.&#xD;
&#xD;
      This substudy therefore aim to investigate the relation between oxygen therapy in COPD&#xD;
      patients admitted with acute exacerbation, oxidative stress, and mortality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxidative stress levels (systemic and lung 8-isopropane levels).</measure>
    <time_frame>Immediately after study completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammation levels (systemic and lung IL-8 levels)</measure>
    <time_frame>Immediately after study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-day all-cause mortality and 30-day all-cause mortality</measure>
    <time_frame>30 days</time_frame>
    <description>extracted from the Danish national registries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>over-all length of hospital stay</measure>
    <time_frame>Immediately after study completion</time_frame>
    <description>calculated from the hospital records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory acidosis</measure>
    <time_frame>Immediately after the procedure</time_frame>
    <description>measured as an arterial blood gas analysis with pH &lt; 7.35 and hypercapnia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>High oxygen saturation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peripheral oxygen saturation level &gt;94% Intervention: Drug: Oxygen gas</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low oxygen saturation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peripheral oxygen saturation level 88-92% Intervention: Drug: Oxygen gas</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>Administering oxygen to achieve the desired peripheral oxygen saturation</description>
    <arm_group_label>High oxygen saturation</arm_group_label>
    <arm_group_label>Low oxygen saturation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18 years or older&#xD;
&#xD;
          -  ability to give informed consent&#xD;
&#xD;
          -  previously diagnosed COPD (either confirmed diagnosis at prior hospital - contact or&#xD;
             from their general practitioner or confirmed diagnosis by the treating physician in&#xD;
             the emergency department (verified by use of relevant medication))&#xD;
&#xD;
          -  admitted with acute exacerbation (acute and worsened shortness of breath) of COPD&#xD;
&#xD;
          -  requiring oxygen treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Instability at arrival requiring immediate lifesaving treatment, e.g. intubation or&#xD;
             non-invasive ventilation, within the first 30 minutes&#xD;
&#xD;
          -  Expected total length of stay in hospital &lt; 12 hours&#xD;
&#xD;
          -  Planned transfer to another hospital within 12 hours&#xD;
&#xD;
          -  Unwilling to have repeated arterial blood gas analyses within the first 12 hours&#xD;
&#xD;
          -  Patients judged terminal by treating physician in the emergency department&#xD;
&#xD;
          -  Non-residents of the particular country&#xD;
&#xD;
          -  Expected impossible follow-up&#xD;
&#xD;
          -  Fertile women (&lt;50 years of age) with positive urine human gonadotropin (hCG) or&#xD;
             plasma-hCG&#xD;
&#xD;
          -  Prior participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mikkel Brabrand, MD, Ph.D</last_name>
    <phone>+4540736373</phone>
    <email>mikkel.brabrand@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital of Southern Denmark, Esbjerg</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Mikkel Brabrand</last_name>
      <phone>+4540736373</phone>
      <email>mikkel.brabrand@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kolding Hospital, Sygehus Lilleb√¶lt</name>
      <address>
        <city>Kolding</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Daugaard Thuesen, MD, Ph.D</last_name>
      <email>Anne.Daugaard.Thuesen2@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Simon Thorgaard-Rasmussen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sydvestjysk Hospital</investigator_affiliation>
    <investigator_full_name>Mikkel Brabrand</investigator_full_name>
    <investigator_title>Professor, ph.d., MD</investigator_title>
  </responsible_party>
  <keyword>oxygen</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

